GPR54 AGONISTS OR ANTAGONISTS FOR TREATMENT OF DISEASES PRESENTING BEHAVIORAL ABNORMALITIES

Michal Eisenbach-Schwartz; Gil M Lewitus; Michal Cardon-Yaakov; Noga Ron-Harel

GPR54 AGONISTS OR ANTAGONISTS FOR TREATMENT OF DISEASES PRESENTING BEHAVIORAL ABNORMALITIES

Michal Eisenbach-Schwartz (Inventor), Gil M Lewitus (Inventor), Michal Cardon-Yaakov (Inventor), Noga Ron-Harel (Inventor)

Biology

Technion - Israel Institute of Technology

Research output: Patent

Abstract

Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide thereof for the treatment of schizophrenia

Original language	American English
Patent number	US2012135935 AA
IPC	A61P 25/ 24 A I
Priority date	27/05/10
State	Published - 31 May 2012

Cite this

@misc{f4e83461271c42e19d91083a4dc0bc4f,

title = "GPR54 AGONISTS OR ANTAGONISTS FOR TREATMENT OF DISEASES PRESENTING BEHAVIORAL ABNORMALITIES",

abstract = "Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide thereof for the treatment of schizophrenia",

author = "Michal Eisenbach-Schwartz and Lewitus, {Gil M} and Michal Cardon-Yaakov and Noga Ron-Harel",

year = "2012",

month = may,

day = "31",

language = "American English",

type = "Patent",

note = "US2012135935 AA; A61P 25/ 24 A I",

}

TY - PAT

T1 - GPR54 AGONISTS OR ANTAGONISTS FOR TREATMENT OF DISEASES PRESENTING BEHAVIORAL ABNORMALITIES

AU - Eisenbach-Schwartz, Michal

AU - Lewitus, Gil M

AU - Cardon-Yaakov, Michal

AU - Ron-Harel, Noga

PY - 2012/5/31

Y1 - 2012/5/31

N2 - Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide thereof for the treatment of schizophrenia

AB - Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide thereof for the treatment of schizophrenia

M3 - Patent

M1 - US2012135935 AA

ER -